Actelion: Another strong quarter and two upcoming launches
BUY, Fair Value CHF67 (+1%)
Momentum still looks very good for Actelion. Ahead of the expected approval of Opsumit (macitentan) in the US tomorrow, Actelion has issued strong quarterly figures today, a touch above expectations. Sales were up 4% in local currencies for the first nine months, up from 3% in H1 whereas Core EPS sustained the high level of growth already reported in the first half i.e. +21%. We were anticipating a slowdown based on an increased level of investments in R&D (entry of cadazolid in phase III) and in SG&A (preparation for launch of Opsumit). Admittedly operating expenses were slightly on the upside, but revenues were a bit higher than expected whereas share buybacks helped the bottom line. In all, this was another very good quarter. All lights are at green for Actelion!
Full report available to subscribers
Please contact firstname.lastname@example.org